LSL Pharma Group Says Secures $1.4 Million in New Orders, Completes Steri-Med Production Scale Up
LSL Pharma Group Q2 Net Loss Halves, While Revenue Jumps 106%
Press Release: LSL PHARMA GROUP REPORTS RECORD REVENUES FOR THE SECOND QUARTER 2024
LSL Pharma Group Announces Voting Results of Its Annual and Special Meeting of Shareholders
LSL Pharma to Raise $4.5 Million Via Private Placements
LSL Pharma Group Inc: AUDITED ANNUAL FINANCIAL STATEMENTS EN
LSL Pharma Group Inc: MDA EN
LSL Pharma Group Brief: Said Earlier Wednesday It Secured $3.8 Million As the Second And Final Tranche Of Its Private Placement Of Units
LSL Pharma Group Brief: Has Upsized Its Private Placement From $3.5 Million To $7.5 Million
Update: LSL Pharma Loses 5% As Raises $6.44 Million In First Closing Of Private Placements
LSL Pharma Raises $6.44 Million In First Closing Of Private Placements
LSL Pharma Group Announced An Extension Of Its Convertible Debentures Offering
LSL Pharma Group Announces an Extension of Its Convertible Debentures Offering
LSL Pharma Group Announces Closing of Second Tranche of Convertible Debentures Offering
LSL Pharma Group Appoints Luc Mainville as Chief Financial Officer
LSL Pharma Group Inc. GAAP EPS of -C$0.01, Revenue of C$2.5M
LSL Pharma Group Announces Closing of First Tranche of Convertible Debentures Offering
Groupe LSL Pharma Announces New Orders With an Annual Revenue Potential in Excess of $2.6 Million
LSL Pharma Group Announces Exclusive Distribution Agreement With Fera Pharmaceuticals to Alleviate Drug Shortage in U.S. Hospitals
LSL Pharma Group Engages Paradox as Investor Relations Services Provider